cevidoplenib

selective spleen tyrosine kinase inhibitor

Also Known As:

SKI-O-703; cyclopropyl-(5-((4-(4-(((4S)-4-hydroxy-1,2-oxazolidin-2-yl)methyl)-3-methylpyrazol-1-yl)pyrimidin-2-yl)amino)-1-methylindol-3-yl)methanone

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Lupus Nephritis 01/01/2023 - "A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models."
2.	Arthritis (Polyarthritis) 01/01/2023 - "In a model of serum-transferred arthritis, SKI-O-703 significantly ameliorated synovitis, with fewer neutrophils and macrophages infiltrated into the synovial tissue. " 01/01/2023 - "A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models."
3.	Synovitis 01/01/2023 - "In a model of serum-transferred arthritis, SKI-O-703 significantly ameliorated synovitis, with fewer neutrophils and macrophages infiltrated into the synovial tissue. "
4.	Autoimmune Diseases (Autoimmune Disease) 01/01/2023 - "These results demonstrate that the novel selective Syk inhibitor SKI-O-703 attenuates the progression of autoantibody-mediated autoimmune diseases by inhibiting both autoantibody-producing and autoantibody-sensing cells."